Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81

Liu,Xiaojing; Chen,Na; Lin,Shumei; Liu,Min

doi:10.3892/ijmm.2016.2459

Synthesized peptide 710-725 from HCV subtype 1a E2 glycoprotein blocks HCV infection through competitive binding of CD81

Authors:
- Xiaojing Liu
- Na Chen
- Shumei Lin
- Min Liu
View Affiliations

Affiliations: Department of Infectious Diseases, The First Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 19, 2016 https://doi.org/10.3892/ijmm.2016.2459
Pages: 836-842

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis C virus (HCV) infection is a significant public health problem worldwide. However, there is still a lack of effective therapeutic drugs which could be used for the interruption of the disease. In the present study, for the first time, we reported that a synthesized peptide, which was synthesized by solid phase peptide synthesis and derived from the amino acids 710 to 725 of the HCV E2, functioned as an inhibitor of HCV infection. Using an MTT assay, we found that the E2 (710-725) peptide exerted no specific cytotoxicity on Huh7.5 cells and primary human hepatocytes (pHH). Interestingly, E2 (710-725) peptide blocked the entry of cell culture‑derived HCV (HCVcc) into hepatocytes. Moreover, it suppressed HCV RNA replication and HCV-specific protein NS3 and NS5B expression, as shown by western blot analysis. Moreover, E2 (710-725) markedly attenuated the inhibitory effect of HCVcc on hepatocyte viability. Additionally, a co-immuninoprecipitation assay demonstrated that E2 (710-725) abrogated the interaction between CD81 and HCV E2 envelope protein through competitive binding of CD81. Overall, our results revealed that the synthesized peptide E2 (710-725) blocked CD81‑mediated HCV entry and possessed the potential to treat HCV infection. Thus, the present study provided novel insights into the development of new drugs for preventing HCV infection.

View Figures

View References

1	Wasley A and Alter MJ: Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis. 20:1–16. 2000. View Article : Google Scholar : PubMed/NCBI
2	Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J and Foung SK: Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol. 79:13199–13208. 2005. View Article : Google Scholar : PubMed/NCBI
3	Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al POSITRON Study: FUSION Study: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 368:1867–1877. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, et al VALENCE Investigators: Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 370:1993–2001. 2014. View Article : Google Scholar : PubMed/NCBI
5	Carrère-Kremer S, Montpellier C, Lorenzo L, Brulin B, Cocquerel L, Belouzard S, Penin F and Dubuisson J: Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J Biol Chem. 279:41384–41392. 2004. View Article : Google Scholar : PubMed/NCBI
6	Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA and Rice CM: Complete replication of hepatitis C virus in cell culture. Science. 309:623–626. 2005. View Article : Google Scholar : PubMed/NCBI
7	Khan AG, Miller MT and Marcotrigiano J: HCV glycoprotein structures: what to expect from the unexpected. Curr Opin Virol. 12:53–58. 2015. View Article : Google Scholar : PubMed/NCBI
8	Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, et al: A genetically humanized mouse model for hepatitis C virus infection. Nature. 474:208–211. 2011. View Article : Google Scholar : PubMed/NCBI
9	Meredith LW, Wilson GK, Fletcher NF and McKeating JA: Hepatitis C virus entry: beyond receptors. Rev Med Virol. 22:182–193. 2012. View Article : Google Scholar : PubMed/NCBI
10	Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G and Abrignani S: Binding of hepatitis C virus to CD81. Science. 282:938–941. 1998. View Article : Google Scholar : PubMed/NCBI
11	Bartosch B, Dubuisson J and Cosset FL: Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med. 197:633–642. 2003. View Article : Google Scholar : PubMed/NCBI
12	Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, et al: Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol. 82:569–574. 2008. View Article : Google Scholar :
13	Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H and Leroux-Roels G: Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 48:1761–1768. 2008. View Article : Google Scholar : PubMed/NCBI
14	Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F and Dubuisson J: Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol. 88:10584–10597. 2014. View Article : Google Scholar : PubMed/NCBI
15	Keck ZY, Angus AG, Wang W, Lau P, Wang Y, Gatherer D, Patel AH and Foung SK: Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412–423. PLoS Pathog. 10:e10042972014. View Article : Google Scholar
16	Qin ZL, Ju HP, Gao TT, Wang WB, Ren H, Zhao P and Qi ZT: Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry. J Gen Virol. 96:1389–1399. 2015. View Article : Google Scholar : PubMed/NCBI
17	Albecka A, Montserret R, Krey T, Tarr AW, Diesis E, Ball JK, Descamps V, Duverlie G, Rey F, Penin F and Dubuisson J: Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol. 85:1777–1792. 2011. View Article : Google Scholar :
18	Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brand-enburg K, et al: A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis. 205:1654–1664. 2012. View Article : Google Scholar : PubMed/NCBI
19	Liu S, McCormick KD, Zhao W, Zhao T, Fan D and Wang T: Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology. 56:484–491. 2012. View Article : Google Scholar : PubMed/NCBI
20	Bukong TN, Kodys K and Szabo G: A novel human radixin peptide inhibits hepatitis C virus infection at the level of cell entry. Int J Pept Res Ther. 20:269–276. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lü X, Yao M, Zhang JM, Yang J, Lei YF, Huang XJ, Jia ZS, Ma L, Lan HY, Xu ZK and Yin W: Identification of peptides that bind hepatitis C virus envelope protein E2 and inhibit viral cellular entry from a phage-display peptide library. Int J Mol Med. 33:1312–1318. 2014.PubMed/NCBI
22	Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, et al: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 11:791–796. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T and Chisari FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 102:9294–9299. 2005. View Article : Google Scholar : PubMed/NCBI
24	Blanco-Canosa JB and Dawson PE: An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. Angew Chem Int Ed Engl. 47:6851–6855. 2008. View Article : Google Scholar : PubMed/NCBI
25	Alsaleh K, Delavalle PY, Pillez A, Duverlie G, Descamps V, Rouillé Y, Dubuisson J and Wychowski C: Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. J Virol. 84:12515–12528. 2010. View Article : Google Scholar : PubMed/NCBI
26	Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, et al: Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology. 51:1144–1157. 2010. View Article : Google Scholar : PubMed/NCBI
27	Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH and Ball JK: Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol. 80:8695–8704. 2006. View Article : Google Scholar : PubMed/NCBI
28	Drummer HE, Boo I, Maerz AL and Poumbourios P: A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol. 80:7844–7853. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zhang J, Randall G, Higginbottom A, Monk P, Rice CM and McKeating JA: CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol. 78:1448–1455. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ji C, Liu Y, Pamulapati C, Bohini S, Fertig G, Schraeml M, Rubas W, Brandt M, Ries S, Ma H and Klumpp K: Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. Hepatology. 61:1136–1144. 2015. View Article : Google Scholar
31	Mekky RY, El-Ekiaby NM, Hamza MT, Elemam NM, El-Sayed M, Esmat G and Abdelaziz AI: Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. J Infect. 70:78–87. 2015. View Article : Google Scholar
32	Zhang YY, Zhang BH, Ishii K and Liang TJ: Novel function of CD81 in controlling hepatitis C virus replication. J Virol. 84:3396–3407. 2010. View Article : Google Scholar : PubMed/NCBI
33	Cartier F, Marcq I, Douam F, Ossart C, Regnier A, Debuysscher V, Lavillette D and Bouhlal H: The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS One. 9:e996012014. View Article : Google Scholar : PubMed/NCBI
34	Al Olaby RR, Cocquerel L, Zemla A, Saas L, Dubuisson J, Vielmetter J, Marcotrigiano J, Khan AG, Vences Catalan F, Perryman AL, et al: Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One. 9:e1113332014. View Article : Google Scholar : PubMed/NCBI